Germline <i>CDH1</i> Variants and Lifetime Cancer Risk
Carrie E. Ryan(University at Buffalo, State University of New York), Jeremy L. Davis(National Institutes of Health), Grace‐Ann Fasaye(National Institutes of Health), Christine Drogan(University of Chicago), Sarah G. Samaranayake(National Institutes of Health), Kerry Kingham(Cargill (Netherlands)), Joshua N. Sampson(National Institutes of Health), Lauren A. Gamble(National Institutes of Health), Linda Rodgers(Massachusetts General Hospital), Anna Duemler(National Institutes of Health), Ava Siegel(Massachusetts General Hospital), Sonia S. Kupfer(University of Chicago), Andrew M. Blakely(National Institutes of Health), Amber F. Gallanis(National Institutes of Health), Daniel C. Chung(Massachusetts General Hospital), Devanshi Patel(Massachusetts General Hospital), James M. Ford(Palo Alto University), James G. Dowty(The University of Melbourne), Paul H. McClelland(National Institutes of Health)
Cited by 61
Related Papers
Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis and Modulates the Tumor-Immune Microenvironment
|Cell Host & Microbe|2013|2.7k
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
|Nature Medicine|2004|2k
Gastroenteropancreatic neuroendocrine tumours
|The Lancet Oncology|2008|1.8k
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
|Clinical Cancer Research|2016|1.2k
Celecoxib for the Prevention of Sporadic Colorectal Adenomas
|New England Journal of Medicine|2006|1k